Skip to main content
OpenTrials
Completed

NCT Number: NCT03858998

Reducing Post-Hospital Mortality in HIV-infected Adults in Tanzania

This research is being done to assess the efficacy of a case management intervention to improve the one year mortality rate of hospitalized, HIV-infected, Tanzanian adults.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Busisi Health Center, Busisi, Mwanza Region, Tanzania

Loading trial locations.

About this study

This research is being done to assess the efficacy of a case management intervention to improve the one year mortality rate of hospitalized, HIV-infected, Tanzanian adults. The study is being conducted at hospitals in Mwanza, Tanzania. 500 participants will be enrolled: 250 will be randomized to the case management intervention and 250 will randomized to routine clinical care. The case management intervention consists of 5 sessions over 90 days, and is designed to link hospitalized, HIV-infected patients to long term care at an HIV clinic. Participants will be followed for two years in order to evaluate primary and secondary study objectives.

Secondary outcome measures time frames have been updated to add the 24-month time point for consistency with the pre-specified endpoints in the study protocol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • HIV-infected
  • ART (anti-retroviral therapy) naïve or have been on ART but have not used ART for > 7 days
  • Lives in the region of Mwanza
  • Able to be referred to an HIV clinic inside the region of Mwanza
  • Has mobile phone or access to mobile phone
  • Planning to stay in the region of Mwanza for the next 24 months
  • Able to speak Kiswahili or English
  • Capable and willing to provide informed consent
  • Willing to provide locator information and two designated contact persons
  • Willing to have a home visits from a study team member

Exclusion criteria

  • Pregnant
  • On anti-retrovirals at hospital admission and already linked to an HIV clinic
  • Medical, psychiatric or psychological condition that, in the opinion of the site investigator, would interfere with completion of study procedures

Treatment and study plan

Case Management Intervention

Other

A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.

Control

Other

Current routine HIV care in Tanzania.

Primary outcomes

  1. Number of Participant Deaths in the First 12 Months Post-hospitalization

    Time frame: 12 months

    The number of participants who die in the first 12 months post-hospitalization will be recorded. Death will be determined by phone calls to relatives and will be confirmed by verbal autopsies, obituaries, hospital records, or death certificates.

Secondary outcomes

  1. Number of Participants Who Attended HIV Clinic

    Time frame: 3, 6, 9,12, and 24 months

    HIV clinic attendance will be monitored by review of HIV clinic records. HIV clinic attendance is defined as alive and attended clinic within a window of 90 days (+/- 45 days) around the time points.

  2. ART Adherence

    Time frame: 3, 6, 9, 12, and 24 months

    ART adherence will be assessed using the ACTG 4-Day ART Recall Questionnaire. Adherence will be calculated as a percentage, using 1 - (number of missed doses/number of prescribed doses).

  3. Viral Suppression

    Time frame: 12 and 24 months

    Suppressed viral load will be defined as a binary outcome based upon the WHO definition of viral suppression as a plasma HIV-1 RNA level <1000 copies/µl.

  4. Traditional Health Beliefs

    Time frame: Baseline,12, and 24 months

    Traditional health beliefs will be assessed at baseline and after 12 months using the HIV Insights and Beliefs Scale, scored from 0 to 6, where higher scores indicate more traditional health beliefs. The minimum value is 0 and the maximum value is 6.

  5. Self-Efficacy

    Time frame: Baseline, 12, and 24 months

    Self-efficacy will be assessed at baseline and after 12 months using the HIV Adherence Self-Efficacy Scale, scored from 0 to 25, where higher scores indicate a higher level of self-efficacy.

  6. Stigma

    Time frame: Baseline, 12, and 24 months

    Stigma will be assessed at baseline and after 12 months using questions based off the AIDS-Related Stigma Scale, scored from 0 to 8, where higher scores indicate a higher level of perceived stigma.

  7. Social Support

    Time frame: Baseline, 12, and 24 months

    Social support will be assessed at baseline and after 12 months using the SPS-10 Scale, scored from 0 to 40, where higher scores indicate a higher level of social support.

  8. Perceived Need for HIV Services

    Time frame: Baseline, 12, and 24 months

    Perceived need for HIV services will be assessed at baseline and after 12 months using the ART Medications Attitude Scale, scored from 0 to 4, where higher scores indicate a lower perceived need for HIV services.

  9. SF-12 Health Survey: Physical and Mental Health

    Time frame: Baseline, 12, and 24 months

    Physical weakness will be assessed at baseline and after 12 months using the SF-12 Health Survey. The SF-12 measures physical health (physical component score (PCS)), scored from 0 to 100, and mental health (mental component score (MCS)), scored from 0 to 100, with higher scores indicating greater physical and mental health.

  10. Acceptability

    Time frame: 12 and 24 months

    Qualitative interviews will be conducted with a sub-set of participants to evaluate the acceptability of the intervention. The acceptability of the Daraja intervention was defined as a binary outcome based on the results of the qualitative interviews. The sub-set will be comprised of 20 intervention participants, 20 routine care control participants, and 20 health care workers (nurses and physicians). Health care workers were not enrolled as participants in the trial nor randomized to a study arm.

  11. Incremental Cost of the Intervention

    Time frame: 12 months

    A microcosting analysis was conducted to identify the resources needed to implement and sustain the Daraja intervention and estimate the associated costs. Resource identification was accomplished primarily through in-person site visits and semi-structured interviews with relevant personnel. Nationally representative unit costs were assigned to the relevant resources. Resources were categorized as fixed start-up, time-dependent, or variable, and contextualized as being required for implementation or sustainment. The intervention implementation period was defined as the first 12 months following start-up, and consisted of the resources in all 3 of the aforementioned categories, and the sustainment period is intended to reflect a typical year following the implementation period, and consists of time-dependent and variable resources, given that the costs associated with fixed start-up resources become negligible over time. Incremental cost was reported as a number in 2023 USD.

  12. Cost Per Life Saved

    Time frame: 12 months

    The difference in costs between the arms from the healthcare perspective will be compared to the observed difference in survival between the arms to calculate incremental cost per life saved. Parametric methods based on parameters obtained from bootstrapping will be used to estimate an acceptability curves, which will illustrate the probability that the intervention is a good value for different willingness-to-pay thresholds

Sponsors and collaborators

Lead sponsor

Weill Medical College of Cornell University

Other

Collaborators

  • National Institute of Mental Health (NIMH)

Registry information

Important dates

Study start
2019
Primary completion
2023
Study completion
2024
First posted
Mar 1, 2019
Registry last updated
Apr 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.